

Executive Summary

Syntr Health Technologies has developed and patented a medical device that can microsize a patient's own adipose tissue at the point-of-care to aid in combating aging-related medical conditions in the growing elderly population.

Problem

As we age, loss of facial fat is inevitable. Our skin becomes saggy and wrinkled and our age lines become more pronounced. Unfortunately, the current approaches to resolve this issue are temporary fixes like using soft tissue fillers such as Juvéderm™, Restylane™ or Sculptra™. Although this solution is easily accessible and may appear more affordable, their use may lead to scarring or blockage of blood vessels if not injected correctly. Their overuse may lead to an unnatural appearance and add weight to the face. There is high demand for a more natural approach and fat transfer provides a more desirable option by both plastic surgeons and individuals looking for a more youthful appearance. The fat transfer market for aesthetics is currently at \$2.1 Billion and expected to grow to \$4.9 Billion by the year 2030.

Solution

To solve this problem, the SyntrFuge™ System microsized the patient's own fat tissue through minimal manipulation while maintaining its structural and supportive properties to aid in tissue repair and restore volume. By means of mechanical stress, our device microsized the patients' own fat tissue while priming the cells' biochemical signals to produce a high-quality fat graft. Our SyntrFuge™ System offers an automated, point-of-care approach to the microsizing of adipose tissue. The system is comprised of a reusable table-top device (SyntrFPU 360™) and single-use sterile consumables (SyntrFuge™) intended for the close-loop processing and transferring of autologous adipose tissue.

The entire process involves four easy steps:

1. Harvest adipose tissue under local anesthesia via syringe vacuum liposuction
2. Cleanse lipoaspirate (fat) and fill AdipoChambers and assemble the SyntrFuge System
3. Place SyntrFuge system in SyntrFPU360 for processing (microsizing of adipose tissue in a repeatable and reproducible manner)
4. Retrieve microsized adipose tissue from AdipoChambers and reinject into the treatment site using a blunt cannula

These steps are performed in the same surgical area. This part of the process enables the microsizing of the adipose tissue within minutes and with reproducible results each time.

Contact Information

Ahmed Zobi, CEO
azobi@syntrtech.com
562-688-9335

Management Team

- **Ahmed Zobi**,
Chief Executive Officer / Co-founder
- **Hugo Salas**,
VP Business Development / Co-founder
- **Justin Stovner**,
VP Engineering / Co-founder
- **Adrian Bahani**,
Product Design

Advisors

Dane Shackleford – Sales & Marketing
Ron King, PhD, MBA – Clinical Research
Nevine Erian, MSQA, MBA – Regulatory
Hisham Seify, MD, Board-Certified Plastic Surgeon
Ghada Y. Afifi, MD, Board-Certified Plastic Surgeon, President of OCSPS
Vance Gardner, MD – Medical Director Hoag Orthopedics Center

Corporate Attorney – Wilson Sonsini
IP Attorney – Knobbe Martens
Accountant – CLA

Corporate Information

Syntr Health Technologies, Inc.
Year Incorporated: 2016
State & Type: Delaware, C-Corp

Raising **\$10,000,000**

Current Funding

Grants (SBIR)(Phase I)	\$300,000
Plastic Surgery Foundation	\$50,000
Founders	\$60,000
Seed Round	\$2,200,000
Series A Bridge	\$1,200,000
Business Plan Competitions	\$54,000